Original language of petition: English
We, the undersigned, citizens and residents of Canada, call upon the House of Commons in Parliament assembled to:
Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive brain tumor that is difficult to diagnose and treat. DIPG, in combination with other gliomas, has been the third most common cancer in children in Canada ages 0-14 (2011-2020). The Government of Canada recognizes the importance of raising cancer awareness, and contributing to cancer research to advance detection efforts and treatment options.
In Canada, May is widely recognized as Brain Tumour Awareness Month, while October 24th is recognized as Brain Cancer Awareness Day. International Childhood Cancer Day is recognized on February 15th, and September is Childhood Cancer Awareness Month. These days of recognition are in addition to National Cancer Wellness Awareness Day on June 26th, and World Cancer Day on February 4th. Further information regarding these health promotion days is available on the Government of Canada’s website: https://www.canada.ca/en/health-canada/services/calendar-health-promotion-days.html.
New DIPG research may provide the key to improved treatment options. The Public Health Agency of Canada (PHAC) monitors cancer in children, and supports childhood cancer research, including DIPG, through the Cancer in Young People in Canada (CYP-C) program. This program makes data on cancer among children and youth available for research and aims to improve outcomes, enhance the quality and accessibility of care, improve survival, and reduce the lasting effects of treatment. CYP-C operates through a collaboration between PHAC, the Canadian Partnership Against Cancer, and the C17 Council, a network of all seventeen children’s cancer hospitals across the country. Further information about CYP-C, Canadian childhood cancer statistics, and access to CYP-C data, is available online: https://health-infobase.canada.ca/data-tools/cypc/publications.html.
Over the last five years (2016-17 to 2020-21), the Canadian Institutes of Health Research (CIHR) invested over one billion dollars in cancer research. Of this amount, $39 million was invested specifically for pediatric cancer research. It is important to note that knowledge acquired in one area of cancer research increases the total knowledge brought to bear in all areas of cancer research.
In April 2019, CIHR launched a Cancer Survivorship Team Grants funding opportunity in partnership with the Canadian Cancer Society. It represents a joint commitment of $10 million for at least four research teams that will address recently identified gaps in cancer survivorship research (including pediatric, adolescent and/or young adult survivorship), such as adverse late and long-term effects associated with cancer treatments.
In March 2020, CIHR provided $2.5 million to the Canadian Collaboration for Child Health: Efficiency and Excellence in the Ethics Review of Research (CHEER), led by Clinical Trials Ontario and the Maternal Infant Child & Youth Research Network. This investment will support the development of research support infrastructure to facilitate multi-site studies for enhanced and expedited pediatric cancer research.
Most recently, Budget 2021 proposed a $30 million investment over two years for CIHR to address gaps in pediatric cancer research and ensure sustainable funding in this area. With this new investment, CIHR has launched a research initiative on pediatric cancer, leveraging its Project Grant Program to support excellent research projects, and through a new funding opportunity, will catalyze the creation of a Pediatric Cancer Consortium.
The Consortium will advance a shared vision to collaborate and produce research that can help inform policy and practice predicated on better science, better access, and better coordination to improve lives of pediatric cancer patients and their families and caregivers. This interconnected consortium will bring together the ecosystem of pediatric cancer research platforms, networks, research teams, policy makers, people with lived/living experience, Indigenous communities and organizations, healthcare providers, and other entities. Applications to the Consortium funding opportunity are open and funding is expected to start in summer 2022.
CIHR has also supported research projects specific to DIPG. Most recently, CIHR provided $639,732 to Dr. James Thomas Rutka and his research team at the Hospital for Sick Children in Toronto for preclinical experiments to determine effective drug use on DIPG tumours. These experiments are essential to the upcoming Phase 1 Clinical Trials planned for children with this disease. CIHR also supported the research of Dr. Andrew Deweyert of the University of Western Ontario to investigate promising new treatments for DIPG. The results of this project will provide key information needed to advance these treatments towards clinical application.
These investments will help improve health systems and health outcomes for pediatric cancer patients and their families.
Only validated signatures are counted towards the total number of signatures.